"The study found a genetic variant associated with weight loss, which was also associated with nausea. People lose more weight if they have this variant."
"Drug trials suggest 14% weight loss on semaglutide (Ozempic and Wegovy) and 20% on tirzepatide (Mounjaro)."
"In this study, based on the experiences of 15,000 people taking weight-loss medications, they lost an average of 11.7% of their body weight during roughly eight months of treatment."
Research indicates that individuals with specific genetic variations related to appetite and digestion experience greater weight loss when using obesity medications such as Wegovy and Mounjaro. These drugs mimic a gut hormone that suppresses hunger. While genetics play a role, factors like sex, age, and geographical background also influence drug efficacy. In a study involving 15,000 participants, average weight loss was 11.7% over eight months, with some individuals losing up to 30%. Genetic analysis revealed a link between certain variants and weight loss outcomes.
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]